TPN171H

TPN171H is a novel, potent, and selective phosphodiesterase type 5 (PDE5) inhibitor developed for the treatment of pulmonary arterial hypertension (PAH) and erectile dysfunction (ED). As a small molecule drug, TPN171H acts by inhibiting PDE5A, leading to increased levels of cyclic guanosine monophosphate (cGMP), which promotes vasodilation in the pulmonary vasculature and corpus cavernosum. Clinical studies have shown that TPN171H is generally safe and well-tolerated in healthy subjects with linear pharmacokinetics over the tested dose range. Unlike some other PDE5 inhibitors, it has minimal impact on blood pressure or color discrimination. The drug has been approved for ED in Uzbekistan and is under regulatory review for ED in China; it remains under clinical development for PAH[1][2][3][4][5][8].

Brand names

AngweidaOnvita昂伟达

Other names

simmerafil